
1. Nat Commun. 2021 Nov 25;12(1):6910. doi: 10.1038/s41467-021-26805-8.

Aberrant integration of Hepatitis B virus DNA promotes major restructuring of
human hepatocellular carcinoma genome architecture.

Álvarez EG(1)(2), Demeulemeester J(#)(3)(4), Otero P(#)(1)(2), Jolly C(#)(3),
García-Souto D(#)(1)(2), Pequeño-Valtierra A(1), Zamora J(1), Tojo M(5), Temes
J(1), Baez-Ortega A(6), Rodriguez-Martin B(1)(2), Oitaben A(1)(2), Bruzos
AL(1)(2), Martínez-Fernández M(1), Haase K(3), Zumalave S(1)(2), Abal R(1),
Rodríguez-Castro J(1), Rodriguez-Casanova A(7)(8), Diaz-Lagares A(7)(9), Li
Y(10), Raine KM(10), Butler AP(10), Otero I(1)(2), Ono A(11), Aikata H(11),
Chayama K(12)(13)(14), Ueno M(15), Hayami S(15), Yamaue H(15), Maejima K(14),
Blanco MG(1), Forns X(16), Rivas C(1)(17), Ruiz-Bañobre J(1)(9)(18)(19),
Pérez-Del-Pulgar S(16), Torres-Ruiz R(20)(21), Rodriguez-Perales S(20),
Garaigorta U(#)(17), Campbell PJ(#)(10)(22), Nakagawa H(#)(14), Van Loo P(#)(3), 
Tubio JMC(23)(24).

Author information: 
(1)Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS),
Universidade de Santiago de Compostela, Santiago de Compostela, 15706, Spain.
(2)Department of Zoology, Genetics and Physical Anthropology, Universidade de
Santiago de Compostela, Santiago de Compostela, 15706, Spain.
(3)The Francis Crick Institute, London, NW1 1AT, UK.
(4)Department of Human Genetics, University of Leuven, Leuven, B-3000, Belgium.
(5)The Biomedical Research Centre (CINBIO), Universidade de Vigo, Vigo, 36310,
Spain.
(6)Department of Veterinary Medicine, University of Cambridge, Cambridge, CB3
0ES, UK.
(7)Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health
Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago
de Compostela (CHUS/SERGAS), Santiago de Compostela, 15706, Spain.
(8)Roche-Chus Joint Unit, Translational Medical Oncology Group (Oncomet), Health 
Research Institute of SantiagodeCompostela(IDIS), Santiago de Compostela, 15706, 
Spain.
(9)Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, 28029,
Spain.
(10)Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10
1SA, UK.
(11)Department of Gastroenterology and Metabolism, Graduate School of Biomedical 
and Health Sciences, Hiroshima University, Hiroshima, Japan.
(12)Collaborative Research Laboratory of Medical Innovation, Graduate School of
Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
(13)Research Center for Hepatology and Gastroenterology, Graduate School of
Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
(14)RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, 230-0045, 
Japan.
(15)Department of Surgery II, Wakayama Medical University, Wakayama, Japan.
(16)Liver Unit, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERehd,
Barcelona, Spain.
(17)Department of Molecular and Cellular Biology, Centro Nacional de
Biotecnología - Consejo Superior de Investigaciones Científicas (CNB - CSIC),
Madrid, 28049, Spain.
(18)Department of Medical Oncology, University Clinical Hospital of Santiago de
Compostela, University of Santiago de Compostela, Santiago de Compostela, 15706, 
Spain.
(19)Translational Medical Oncology Group (Oncomet), Health Research Institute of 
Santiago de Compostela (IDIS), Santiago de Compostela, 15706, Spain.
(20)Molecular Cytogenetics and Genome Engineering Group, Centro Nacional de
Investigaciones Oncológicas (CNIO), Madrid, Spain.
(21)Division of Hematopoietic Innovative Therapies, Centro de Investigaciones
Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain.
(22)Department of Haematology, University of Cambridge, Cambridge, CB2 2XY, UK.
(23)Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS),
Universidade de Santiago de Compostela, Santiago de Compostela, 15706, Spain.
jose.mc.tubio@usc.es.
(24)Department of Zoology, Genetics and Physical Anthropology, Universidade de
Santiago de Compostela, Santiago de Compostela, 15706, Spain.
jose.mc.tubio@usc.es.
(#)Contributed equally

Most cancers are characterized by the somatic acquisition of genomic
rearrangements during tumour evolution that eventually drive the oncogenesis.
Here, using multiplatform sequencing technologies, we identify and characterize a
remarkable mutational mechanism in human hepatocellular carcinoma caused by
Hepatitis B virus, by which DNA molecules from the virus are inserted into the
tumour genome causing dramatic changes in its configuration, including
non-homologous chromosomal fusions, dicentric chromosomes and megabase-size
telomeric deletions. This aberrant mutational mechanism, present in at least 8%
of all HCC tumours, can provide the driver rearrangements that a cancer clone
requires to survive and grow, including loss of relevant tumour suppressor genes.
Most of these events are clonal and occur early during liver cancer evolution.
Real-time timing estimation reveals some HBV-mediated rearrangements occur as
early as two decades before cancer diagnosis. Overall, these data underscore the 
importance of characterising liver cancer genomes for patterns of HBV
integration.

© 2021. The Author(s).

DOI: 10.1038/s41467-021-26805-8 
PMID: 34824211 

